Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - obezita - preparáty proti obezitě, diety - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - léky na léčbu nemocí kostí - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova choroba - antiparkinsonické léky - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - jiné zažívací trakt a produkty metabolismu, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolismus aminokyselin, vrozené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryho choroba - jiné zažívací trakt a produkty metabolismu, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)